Arcutis Biotherapeutics, Inc. ARQT Business Segments — Cost of Sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s business segments — cost of sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s business segments — cost of sales?
- Arcutis Biotherapeutics, Inc. (ARQT) reported business segments — cost of sales of $9.22M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s business segments — cost of sales changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s business segments — cost of sales increased by 57.6% year-over-year, from $5.85M to $9.22M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s business segments — cost of sales?
- Over 3 years (2022 to 2025), Arcutis Biotherapeutics, Inc.'s business segments — cost of sales has grown at a 316.9% compound annual growth rate (CAGR), from $442K to $32.03M.
- What does business segments — cost of sales mean?
- Includes the direct costs attributable to the production and distribution of products sold by the reportable segment. This encompasses manufacturing, raw materials, and logistics expenses required to bring the segment's therapies to market.